FMC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
FMC Corp is not a good buy for a beginner, long-term investor at this moment. The stock is facing significant headwinds, including declining revenue guidance, weak financial performance, and bearish technical indicators. Analysts have lowered price targets, and there are no strong positive catalysts to offset the negative sentiment. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on investing in FMC is the most prudent decision.
The technical indicators are bearish. The MACD is below zero and negatively contracting, the RSI is neutral, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 13.602, with resistance at 15.779. Overall, there are no clear buy signals.
FMC's herbicide rimisoxafen has been classified as the first dual-mode action herbicide, which could provide long-term growth opportunities.
The CEO announced a divestiture process with Bank of America and Goldman Sachs as advisors, which temporarily boosted the stock by 7%.
Revenue guidance for 2026 is projected to decline to $3.6-$3.8 billion.
An 86% dividend cut raises concerns about future growth and investor confidence.
Pomerantz LLP is investigating FMC for potential securities fraud and unlawful business practices.
Analysts have consistently lowered price targets, reflecting weak sentiment.
In Q4 2025, FMC's revenue dropped by 11.52% YoY to $1.08 billion. Net income increased significantly to -$1.72 billion, but this is due to a high negative base effect rather than actual improvement. EPS also increased to -13.74, but remains negative. Gross margin dropped to 39.8%, down 7.14% YoY. Overall, the financial performance is weak.
Analysts have been lowering price targets consistently, with the most recent targets ranging from $14 to $20. The majority of analysts maintain Neutral or Equal Weight ratings, reflecting cautious sentiment. There is no strong buy recommendation from analysts.
